Body test result esp. on liver situation
1 BODY INFORMATION
WEIGHT: BELOW AVERAGE
BLOOD PRESURE: LOOKS OK. BUT normally it is a bit lower than 100. 90-80 for high and 65-45 for low mmHG.
2 LIVER FIBROSIS and STEATOSIS
根据您提供的这份肝脏弹性检测报告，以下是针对**肝纤维化**和**脂肪变**（脂肪肝）结果的详细分析和解读：
这份报告很可能来自**瞬时弹性成像技术（如FibroScan®）**的检查结果。它通过两个核心指标来无创评估肝脏健康状况：
### 1. 肝脏硬度值（E） — 评估 **肝纤维化**
* **中位数（Median）：6.5 kPa**
* **四分位距（IQR）：1.2 kPa**
* **IQR/中位数比值：18%** （这是一个**关键的质量控制指标**。通常认为比值 ≤ 30% 表示结果可靠。**18% 表明测量一致性非常好**，结果高度可信。）
**临床意义解读（常见指南参考）：**
* **正常参考范围：** 通常 < 5.5 - 7.0 kPa（具体阈值因病因不同而异，如病毒性肝炎与代谢性肝病）。
* **6.5 kPa 的意义：** 这个值通常属于**临界范围或轻度纤维化（F0-F1/F2）**。
* 对于疑似代谢相关脂肪性肝病的患者，此值常对应 **无明显纤维化（F0-F1）**。
* 它可能提示最早期的纤维化（F1阶段），但**极不可能代表进展期纤维化（≥F3）或肝硬化（F4）**。
**关于纤维化的结论：** 结果提示肝脏**不存在具有临床意义的显著纤维化**。鉴于测量质量极佳（IQR/中位数比18%），这是一个非常令人安心的数值。
### 2. 受控衰减参数（MAP） — 评估 **肝脂肪变（脂肪肝）**
* **中位数（Median）：213 dB/m**
* **四分位距（IQR）：13 dB/m**
**临床意义解读（常见CAP™阈值参考）：**
* **S0（无脂肪肝）：** < 248 dB/m
* **S1（轻度脂肪肝）：** 248 - 268 dB/m
* **S2（中度脂肪肝）：** 268 - 280 dB/m
* **S3（重度脂肪肝）：** > 280 dB/m
*（注：具体阈值可能因设备及人群略有不同）*
**关于脂肪变的结论：** 213 dB/m 的数值**低于常见的轻度脂肪肝阈值**。这表明肝脏**没有明显的脂肪浸润，即没有脂肪肝**。
### 3. 整体数据与背景信息
* **10次个体测量值**在肝脏硬度和衰减参数上都表现出良好的一致性。
* **检测成功率：100%** —— 从技术上讲，本次检查非常成功。
* **备注：“病史不详”** —— 这是一个重要的局限。结果的最终解释必须结合患者的**个人风险因素**（如肥胖、糖尿病、饮酒史、病毒性肝炎史等）才有最大价值。
### 总结与核心洞察
* **总体印象：这是一份非常理想的检查报告。** 肝脏既**没有明显的脂肪变性**，也**没有显著的纤维化**迹象。
* **可能的临床场景：**
1. **筛查：** 如果这是一位有风险因素（如肥胖）人士的筛查，结果极佳，表明肝脏目前很健康。
2. **随访：** 如果患者有已知的肝脏问题，此结果表明疾病稳定、没有进展，或治疗反应良好。
3. **排查肝酶升高原因：** 此结果基本可以排除进展期纤维化或重度脂肪肝是导致转氨酶升高的原因。
* **局限性与后续建议：**
* 瞬时弹性成像是一种筛查和监测工具，并非像肝穿刺活检那样的金标准诊断方法。
* 结果应结合患者的**血液检查**（特别是转氨酶、血小板）、**完整病史**和**影像学**（如超声）进行综合判断。
* 鉴于结果正常，后续重点应是**管理和控制任何潜在的风险因素**（如控制体重、管理血糖、限制饮酒）以维持肝脏健康。
* 根据临床具体情况，可能建议在 **1-3年后** 进行复查以进行长期监测。
**简而言之，这份报告描绘了一个在硬度和脂肪含量方面都处于健康范围的肝脏。** 临床医生的下一步将是把这些数据整合到患者的整体健康状况中进行全面评估。
Based on the data provided, this appears to be the result sheet from a non-invasive liver examination, likely using a technology like **Transient Elastography (FibroScan®)** or a similar shear wave elastography device. The report measures two key parameters:
1. **Liver Stiffness (E):** An indicator of **fibrosis** (scarring).
2. **Attenuation Parameter (MAP/CAP):** An indicator of **steatosis** (fatty liver).
Here is a breakdown and clinical interpretation of the results:
### 1. Liver Stiffness (Fibrosis Assessment)
* **Median Value:** **6.5 kPa**
* **Interquartile Range (IQR):** 1.2 kPa
* **IQR/Median:** 18% (This is a **key quality indicator**. A result is generally considered reliable if IQR/Median ≤ 30%. **18% is excellent**, indicating a very consistent measurement).
**Interpretation (Common Guidelines):**
* **Normal Range:** Typically < 5.5 - 7.0 kPa (varies by cause, e.g., viral vs. metabolic).
* **6.5 kPa** generally falls within the **Gray Zone or Mild Fibrosis (F0-F1/F2)** range.
* For a patient with suspected Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), this value often corresponds to **no significant fibrosis (F0-F1)**.
* It could indicate the earliest stage of fibrosis (F1) but is **very unlikely to represent advanced fibrosis (≥F3) or cirrhosis (F4)**.
**Conclusion on Fibrosis:** The result suggests **minimal to no significant liver fibrosis**. It is a reassuring value, especially given the excellent reliability (IQR/Median 18%).
### 2. Attenuation Parameter (Steatosis Assessment)
* **Median Value:** **213 dB/m**
* **Interquartile Range (IQR):** 13 dB/m
**Interpretation (Common CAP™ Cut-offs for Steatosis Grading):**
* **S0 (No steatosis):** < 248 dB/m
* **S1 (Mild steatosis):** 248 - 268 dB/m
* **S2 (Moderate steatosis):** 268 - 280 dB/m
* **S3 (Severe steatosis):** > 280 dB/m
*(Note: Exact cut-offs can vary slightly by device and population)*
**Conclusion on Steatosis:** A value of **213 dB/m is below the common S1 threshold**. This indicates **no evidence of significant fatty liver (steatosis)**.
### 3. Individual Measurements & Overall Context
* The ten individual measurements show good consistency for both E and MAP values.
* **Success Rate: 100%** – The exam was technically successful on all attempts.
* **Remark: "Medical history is unknown."** – This is a crucial limitation. Interpretation is best done in the context of the patient's risk factors (e.g., obesity, diabetes, alcohol use, viral hepatitis).
### Summary & Insights
* **Overall Impression:** This is a **very reassuring report**. The liver shows **no signs of significant fatty changes** and **no signs of significant fibrosis**.
* **Possible Clinical Scenarios:**
1. **Screening:** If this was a screening test for an individual with risk factors (like obesity), the result is excellent and suggests the liver is currently healthy.
2. **Follow-up:** For a patient with known liver disease, this result indicates stable, non-progressive disease or effective treatment response.
3. **Evaluation of Elevated Liver Enzymes:** This result effectively rules out advanced fibrosis or severe steatosis as the cause.
* **Limitations & Next Steps:**
* Transient elastography is a screening/surveillance tool, not a definitive diagnostic tool like a biopsy.
* The result should be correlated with the patient's **blood tests** (especially ALT, AST, platelets), **clinical history**, and **imaging** (ultrasound).
* Given the normal findings, the main focus would be on **addressing any underlying risk factors** (weight management, glycemic control, reducing alcohol intake) to maintain liver health.
* Depending on the clinical context, repeat testing in **1-3 years** might be recommended for surveillance.
**In essence, this report depicts a liver that is functionally and structurally within a healthy range regarding stiffness and fat content.** The clinician's next step would be to integrate this data with the full patient profile.
3 Blood Test on liver
Based on the **Liver Function Test** results you provided, all values are within the normal reference ranges, indicating **normal liver function** without significant abnormalities.
---
### ✅ **Summary of Key Indicators**:
1. **Total Protein, Albumin, Globulin** → Within normal range, good nutritional and synthetic function.
2. **Albumin/Globulin Ratio** → Normal, no significant inflammation or immune abnormalities.
3. **Total Bilirubin, Direct Bilirubin** → Normal, no obvious bile duct obstruction or hemolysis.
4. **Indirect Bilirubin** → Slightly above the upper limit (12.31 vs. 12.0 μmol/L). Mild elevation can be due to individual variation, slight hemolysis, or Gilbert's syndrome—usually not clinically significant.
5. **ALP, GGT, AST, ALT** → All normal, indicating no significant liver cell damage and clear bile ducts.
---
### 📌 **Conclusion**:
- **Overall liver function is normal**.
- If indirect bilirubin remains slightly elevated without symptoms, consider **Gilbert's syndrome** (a benign hereditary condition).
- Maintain a healthy diet, exercise moderately, avoid alcohol, and consider periodic follow-up.
If you have other symptoms or concerns, it's advisable to consult a doctor for further evaluation.
4 Blood test on liver last month - 5 11 2025
2025 12 28
Comments
Post a Comment